Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matko Kalac

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti|November 30, 2007
[The disappearance of CD20 positive lymphocytes in the pleural effusion after intrapleural application of rituximab]Matko Kalac, Slobodanka Ostojić Kolonić, Ika Kardum-Skelin, et al.
Iscience|December 23, 2020
<i>N</i>-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κBMatko Kalac, Michael Mangone, Alison Rinderspacher, et al.
Blood|August 6, 2013
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphomaJennifer E Amengual, Sean Clark-Garvey, Matko Kalac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2012
Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomasLuigi Scotto, Marianna Kruithof-de Julio, Luca Paoluzzi, et al.
Blood|July 21, 2011
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLMatko Kalac, Luigi Scotto, Enrica Marchi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by ageNeal D Shore, Ugo De Giorgi, Matko Kalac, et al.
Cell Death & Disease|February 7, 2020
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)Xin Xu, Matko Kalac, Michael Markson, et al.
British Journal of Haematology|July 22, 2015
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphomaEnrica Marchi, Kelly M Zullo, Jennifer E Amengual, et al.
European Urology|February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer PatientsAndrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Blood|November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti|November 30, 2007
[The disappearance of CD20 positive lymphocytes in the pleural effusion after intrapleural application of rituximab]Matko Kalac, Slobodanka Ostojić Kolonić, Ika Kardum-Skelin, et al.
Iscience|December 23, 2020
<i>N</i>-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF-κBMatko Kalac, Michael Mangone, Alison Rinderspacher, et al.
Blood|August 6, 2013
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphomaJennifer E Amengual, Sean Clark-Garvey, Matko Kalac, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2012
Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomasLuigi Scotto, Marianna Kruithof-de Julio, Luca Paoluzzi, et al.
Blood|July 21, 2011
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLMatko Kalac, Luigi Scotto, Enrica Marchi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by ageNeal D Shore, Ugo De Giorgi, Matko Kalac, et al.
Cell Death & Disease|February 7, 2020
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL)Xin Xu, Matko Kalac, Michael Markson, et al.
British Journal of Haematology|July 22, 2015
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphomaEnrica Marchi, Kelly M Zullo, Jennifer E Amengual, et al.
European Urology|February 3, 2026
ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer PatientsAndrew J Armstrong, Daniel P Petrylak, Neal D Shore, et al.
Blood|November 17, 2017
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphomaJennifer E Amengual, Renee Lichtenstein, Jennifer Lue, et al.
Pageof 3